Par Pharma arm secures final nod for olanzapine, fluxoxetine hydrochloride capsules

By Admin
Par Pharmaceutical Companies, Inc said its operating subsidiary Par Pharmaceutical, Inc has secured final approval from the U.S. Food and Drug Administ...

Par Pharmaceutical Companies, Inc said its operating subsidiary Par Pharmaceutical, Inc has secured final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for olanzapine and fluxoxetine hydrochloride capsules.

These capsules are in the range of 3mg/25mg (eq base), 6mg/25mg(eq base), 6mg/50mg (eq base), 12mg/25mg (eq base) and 12 mg/50mg (eq base).

Olanzapine and fluxoetine hydrochloride is the generic version of Eli Lilly’s Symbax®    and is indicated to treat depressive episodes associated with bipolar I disorder in adults. 

Par has started shipping all strengths of the product. As per the IMS  Health data, the annual U.S. sales of olanzapine and fluxoetine hydrochloride capsules are around $80 million. The use of olanzapine and fluoxetine is contraindicated with monoamine oxidase inhibitors, primozide and thioridazine.

Par Pharmaceutical Companies, Inc is a privately-held U.S.-based specialty pharmaceutical company that develops, manufactures and markets high-barrier-to-entry generic drugs. It also develops niche, innovative proprietary pharmaceuticals through its wholly-owned subsidiary’s two operating divisions namely Par Pharmaceutical and Strativa Pharmaceuticals

. The company initially traded on the New York Stock Exchange and this year, it agreed to be bought by the private equity company TPG Capital. It is based in U.S. with corporate headquarters in Woodcliff Lake, New Jersey and also has more facilities for research, manufacturing and distribution in Suffern, New York and Spring Valley, New York.

Share
Share

Featured Articles

Oracle's generative AI prioritises patient healthcare

Oracle's vision for better healthcare focuses on improving medical professionals quality time with patients, with Oracle Clinical Digital Assistant

2San's new app provides vital diagnostic product insights

2San’s leap forward in self diagnostics will bring ‘Better Care, Better Life’ to all, in a new step for 2San’s post-COVID-19 healthcare technology

Cylera’s Richard Staynings on healthcare cybersecurity

Richard Staynings, Chief Security Strategist, discusses the challenges facing healthcare cybersecurity & how Cylera's IoT security can protect it

Amazon Prime & One Medical to revolutionise healthcare

Digital Healthcare

Creating robust pharma supply chains with delivery devices

Medical Devices & Pharma

From Ukraine to Myanmar, reports reveal attacks on hospitals

Hospitals